Welcome to our dedicated page for Polomar Health SEC filings (Ticker: PMHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Polomar Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Polomar Health's regulatory disclosures and financial reporting.
Polomar Health Services (PMHS) insider buying disclosed on Form 4. Terrence M. Tierney, President and Director, reported three open-market purchases: 125,000 shares on 06/27/2025, 8,333 shares on 07/15/2025 and 7,695 shares on 08/15/2025, bringing his beneficial ownership to 141,028 shares. Reported aggregate cash amounts are shown for each lot on the form. The Form 4 is signed by the reporting person.
Polomar Health Services, Inc. filed an S-1 describing a recent recapitalization, related-party financings, and material liquidity constraints. The company sold 90,437,591 common shares (about 83% of issued and outstanding) and 500,000 Series A preferred shares to CWR 1, LLC for $350,000. The former CEO and chairman resigned. The filing discloses multiple promissory notes and related-party advances including a Reprise Note with outstanding principal of $716,402.67 and accrued interest of $29,508.91 as of December 31, 2024 (amended and larger balances reported through June 30, 2025), a $150,000 CWR Note II with initial 12% APR and milestone draws, and other notes exchanged for preferred stock.
The company reported no cash equivalents, net loss of $1,341,333 for 2024, accumulated deficit of $2,911,163 as of December 31, 2024 (increased to $3,973,581 as of June 30, 2025), and explicit substantial doubt about its ability to continue as a going concern within one year.
